Monitor upcoming durability data in 2H 2026 and Phase 2b results in 2027, which will be critical for confirming the drug's long-term efficacy and dosing advantage. The strong safety profile reduces regulatory risk for future trials.
ORKA drugs
ORKA drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 27 $76.39entry
- T+1 · 7mo ago −3.14%α −2.66% · $73.99
- T+5 · 7mo ago −13.00%α −13.40% · $66.46
- T+20 · 6mo ago −22.69%α −27.64% · $59.06
- T+60 · 4mo ago +21.13%α +16.35% · $92.53
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Oruka Therapeutics announced positive Phase 2a trial results for its anti-IL-23 antibody ORKA-001 in psoriasis, showing 63.5% of patients achieved complete skin clearance (PASI 100) at 16 weeks with a favorable safety profile. The data supports potential annual dosing and positions ORKA-001 as a best-in-class therapy in a $30B+ market.
Key Facts
- 63.5% of ORKA-001-treated patients achieved PASI 100 (complete skin clearance) at Week 16 vs. 4.8% for placebo (p < 0.0001)
- Favorable safety profile: no serious adverse events in treatment arm, TEAE rate (50.8%) lower than placebo (57.1%)
- Updated PK data supports potential for annual dosing, with drug concentrations remaining above effective levels for a full year
- Phase 2b trial (EVERLAST-B) ongoing with data expected in 2027 to support Phase 3 initiation
- Company is well-funded with cash runway into Phase 3 for ORKA-001
Financial Impact
Significant positive impact on valuation potential in a $30B+ psoriasis market
Risk Factors
- Phase 2a results may not be replicated in larger Phase 3 trials
- Competitors in the IL-23 inhibitor space could respond with improved data or pricing
- Longer-term safety data could reveal issues not seen in the 16-week trial
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-047743 |
| Document: ea028778201ex99-2.htm | 0001213900-26-047743 |
| Document: ea028778201ex99-1.htm | 0001213900-26-047743 |
| Document: 0001213900-26-047743-index-headers.html | 0001213900-26-047743 |
| Document: 0001213900-26-047743-index.html | 0001213900-26-047743 |
| Document: 0001213900-26-047743.txt | 0001213900-26-047743 |
Track record
40 reports on ORKA
7 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 10 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $104.40 Now $99.24 −4.94% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers